A rejection over unreliable trial data and research on higher hospice spending show why evidence and patient outcomes matter alongside new treatments and coverage decisions.
Two recent developments put a central question in American health care into focus: Are patients and taxpayers getting value for what they spend? The FDA’s rejection of a proposed Duchenne muscular dystrophy therapy and new research on Medicare hospice payments highlight the importance of reliable evidence and measurable outcomes.
On Nov. 20, the FDA issued a complete response letter rejecting Capricor Therapeutics’ deramiocel, an investigational cell therapy for Duchenne muscular dystrophy. The agency said the evidence did not establish “substantial evidence of effectiveness.” It also cited serious data-integrity violations, including unauthorized changes to the analysis plan, unblinding-related rule violations and other protocol deviations that compromised the study’s reliability.
The decision does not establish that the therapy cannot help patients. It means the evidence submitted did not satisfy the FDA’s standard. For families facing a progressive disease, that distinction may be painful. But approving a treatment on unreliable trial results would leave patients, clinicians and payers with less reason to trust claims about its benefits. The source material does not describe what path Capricor may pursue next.
Trial details matter as much as headline results. Changes to an analysis plan or compromised blinding can weaken confidence that an apparent effect is real. Regulators must weigh access to promising options against the need for evidence patients and doctors can rely on.
A separate fiscal concern emerges in hospice care. A Health Affairs study found that after private-equity acquisition, Medicare paid $993 more per hospice stay—a 5.9% increase over a $16,922 baseline. Average stays were 6.3 days longer, and patients were more likely to be discharged alive. Researchers found no increase in visits.
The findings do not establish why these differences occurred or show that every private-equity-owned hospice provides poorer care. A longer stay or discharge alive is not, by itself, evidence of inadequate treatment. Still, higher payments, more days of care and no increase in visits raise questions for Medicare and families choosing providers. Medicare’s routine hospice rate is $225 per day for the first two months and $177 per day thereafter, according to a Nov. 22 Morningstar report. The policy question is what care and patient benefit accompany the additional spending.
Evidence and payment are also central to GRAIL’s Galleri blood test, intended to screen for multiple cancers. Support from an FDA advisory panel is a recommendation, not approval. GRAIL said Nov. 4 that it anticipated an FDA decision by early in the first quarter of 2027. As of that report, Galleri was not FDA-cleared or approved. Medicare reimbursement is a separate hurdle: discussions with the Centers for Medicare & Medicaid Services are expected to begin after approval, leaving coverage and affordability unsettled.
Eli Lilly’s drug pipeline shows how treatment prospects can attract attention before they become available to patients. Retatrutide has completed Phase 3 trials, with an FDA filing planned for the first quarter of 2027; the cited report lists best weight loss of 28.3%. Eloralintide remains in Phase 3, while a combination of eloralintide and tirzepatide is scheduled to begin Phase 3 in the fourth quarter of 2026. Results, regulatory review, prices and insurance coverage will determine whether these prospects become practical options.
Across these cases, the test is not simply whether a treatment or service attracts attention. It is whether dependable evidence demonstrates a benefit patients value—and whether public programs pay a price proportionate to that benefit. That standard matters to patients and to taxpayers who finance much of the system.

